ADA and glycogen storage disease VI: Currently, clinical trials of gene therapy with lentiviral vector systems are having a profound impact on several monogenetic diseases, including ADA-SCID, SCID-X1, ALD, MLD, X-CGD, WAS, β-thalassemia, and sickle cell disease [133,134,135,136,137,138].